Neoadjuvant targeted therapies in renal cell carcinoma

Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
Pierre BigotJ-J Patard

Abstract

Targeted molecules are used in the treatment of metastatic kidney cancer. Their use before surgery could reduce tumor volume, facilitate surgical resection and treat micrometastases. In this literature review, we present the main results of studies that evaluated the benefit of targeted therapies in kidney cancer. This article is based on a systematic literature search by using Pubmed database. In prospective studies, a decrease in the size of the primary tumor has been reported to be 9.6 to 28.3%. In case of metastatic kidney cancer, cytoreductive nephrectomy could be possible after targeted therapies in tumors that initially were not available for surgery. In localized kidney cancer, a reduction of tumor volume of more than 30% is obtained in 5 to 45% of cases after neoadjuvant targeted therapies. Their use is associated with the occurrence of the usual side effects of targeted therapies plus a specific risk of delayed healing and metastatic progression during the perioperative period. The study of tumors after surgery shows a lower efficiency of the production of tumor necrosis in non-clear cell carcinomas. Data from the literature are not currently in favor of neoadjuvant use of targeted therapies in the treatment of kidney...Continue Reading

References

Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
May 12, 2007·European Urology·Paul C M S Verhagen
Apr 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Astrid A M van der VeldtEpie Boven
Dec 23, 2008·The Journal of Urology·Anil A ThomasSteven C Campbell
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric JonaschNizar Tannir
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Lance CoweyW Kimryn Rathmell
Apr 17, 2010·BJU International·Jonathan L SilbersteinIthaar H Derweesh
Jul 21, 2010·The Journal of Urology·Nicholas J HellenthalHyung L Kim
Sep 15, 2010·International Journal of Cancer. Journal International Du Cancer·Ingrid M E DesarI Jolanda J M de Vries
Oct 19, 2010·European Urology·E Jason AbelChristopher G Wood
May 31, 2011·European Urology·Brian F ChapinChristopher G Wood
Mar 20, 2012·The Journal of Urology·Brian I RiniSteven Campbell
Oct 12, 2012·OncoTargets and Therapy·Takeshi YuasaJunji Yonese
Aug 24, 2013·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
Feb 4, 2014·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·J-J PatardUNKNOWN Les membres du CCAFU
Apr 15, 2014·Neoplasia : an International Journal for Oncology Research·Gursah Kats-UgurluWilliam Leenders
Jan 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benoit BeuselinckJessica Zucman-Rossi

❮ Previous
Next ❯

Citations

Oct 16, 2019·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·K BensalahA Méjean

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.